High prevalence of epigenetic inactivation of the human four and a half LIM domains 1 gene in human oral cancer

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 141-150

  Koike, Kazuyuki ^a   Kasamatsu, Atsushi ^a,b   Iyoda, Manabu ^a   Saito, Yasuhiro ^a   Kouzu, Yukinao ^a   Koike, Hirofumi ^a   Sakamoto, Yosuke ^b   Ogawara, Katsunori ^b   Tanzawa, Hideki ^a,b   Uzawa, Katsuhiro ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 aza 2' deoxycytidine; Chromatin immunoprecipitation; Four and a half LIM domains 1; Immunohistochemistry; Methylation specific PCR; Oral squamous cell carcinoma; Quantitative reverse transcriptase polymerase chain reaction; Sodium butyrate; Western blotting

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; FHL1 PROTEIN; LIM PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GENETICS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; MOUTH; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA METHYLATION; EPIGENOMICS; FEMALE; GENE SILENCING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIM DOMAIN PROTEINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH; MOUTH NEOPLASMS; MUSCLE PROTEINS; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84873619944     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1677     Document Type: Article

References (44)

1. Lippman SM, Sudbø J and Hong WK: Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 23: 346-356, 2005. (Pubitemid 46206883)
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
3. Bettendorf O, Piffkò J and Bànkfalvi A: Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 40: 110-119, 2004. (Pubitemid 38030353)
4. Kademani D: Oral cancer. Mayo Clin Proc 82: 878-887, 2007. (Pubitemid 47015470)
5. Tatsumoto T, Xie X, Blumenthal R, Okamoto I and Miki T: Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis. J Cell Biol 147: 921-928, 1999.
6. Shinozuka K, Uzawa K, Fushimi K, et al: Downregulation of carcinoembryonic antigen-related cell adhesion molecule 1 in oral squamous cell carcinoma: correlation with tumor progression and poor prognosis. Oncology 76: 387-397, 2009.
7. Brown S, McGrath MJ, Ooms LM, Gurung R, Maimone MM and Mitchell CA: Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytoplasmic communication. J Biol Chem 274: 27083-27091, 1999.
8. McGrath MJ, Mitchell CA, Coghill ID, Robinson PA and Brown S: Skeletal muscle LIM protein 1 (SLIM1/FHL1) induces alpha 5 beta 1-integrin-dependent myocyte elongation. Am J Physiol Cell Physiol 285: C1513-C1526, 2003. (Pubitemid 37429626)
9. Loughna PT, Mason P, Bayol S and Brownson C: The LIM-domain protein FHL1 (SLIM 1) exhibits functional regulation in skeletal muscle. Mol Cell Biol Res Commun 3: 136-140, 2000. (Pubitemid 30430012)
10. Chen DH, Raskind WH, Parson WW, et al: A novel mutation in FHL1 in a family with X-linked scapuloperoneal myopathy: phenotypic spectrum and structural study of FHL1 mutations. J Neurol Sci 296: 22-29, 2010.
11. Oku N, Sasabe E, Ueta E, Yamamoto T and Osaki T: Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 66: 5251-5257, 2006. (Pubitemid 43844949)
12. Sakashita K, Mimori K, Tanaka F, et al: Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol 15: 2293-2300, 2008.
13. Fackler MJ, McVeigh M, Mehrotra J, et al: Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64: 4442-4452, 2004. (Pubitemid 38856915)
14. Fuks F: DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 15: 490-495, 2005. (Pubitemid 41262404)
15. Hassig CA and Schreiber SL: Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1: 300-308, 1997. (Pubitemid 127437155)
16. Huang L: Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol 209: 611-616, 2006. (Pubitemid 44665677)
17. Endo Y, Uzawa K, Mochida Y, et al: Sarcoendoplasmic reticulum Ca(2+) ATPase type 2 downregulated in human oral squamous cell carcinoma. Int J Cancer 110: 225-231, 2004. (Pubitemid 38580395)
18. Shimada K, Uzawa K, Kato M, et al: Aberrant expression of RAB1A in human tongue cancer. Br J Cancer 92: 1915-1921, 2005. (Pubitemid 40826141)
19. Saito K, Uzawa K, Endo Y, et al: Plasma membrane Ca2+ ATPase isoform 1 down-regulated in human oral cancer. Oncol Rep 15: 49-55, 2006.
20. Kasamatsu A, Uzawa K, Nakashima D, et al: Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med 16: 269-273, 2005.
21. Sakuma K, Kasamatsu A, Yamatoji M, et al: Expression status of Zic family member 2 as a prognostic marker for oral squamous cell carcinoma. J Cancer Res Clin Oncol 136: 553-559, 2010.
22. Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H and Tanzawa H: Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res 82: 607-611, 2003. (Pubitemid 41766142)
23. Kouzu Y, Uzawa K, Kato M, et al: WISP-2 expression in human salivary gland tumors. Int J Mol Med 17: 567-573, 2006.
24. Onda T, Uzawa K, Endo Y, et al: Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma. Br J Cancer 94: 698-709, 2006. (Pubitemid 43361902)
25. Sakuma T, Uzawa K, Onda T, et al: Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29: 117-124, 2006.
26. Kato Y, Uzawa K, Yamamoto N, et al: Overexpression of Septin1: possible contribution to the development of oral cancer. Int J Oncol 31: 1021-1028, 2007.
27. Nomura H, Uzawa K, Yamano Y, et al: Overexpression and altered subcellular localization of autophagy-related 16-like 1 in human oral squamous-cell carcinoma: correlation with lymphovascular invasion and lymph-node metastasis. Hum Pathol 40: 83-91, 2009.
28. Iyoda M, Kasamatsu A, Ishigami T, et al: Epithelial cell transforming sequence 2 in human oral cancer. PloS One 5: e14082, 2010.
29. Yamatoji M, Kasamatsu A, Kouzu Y, et al: Dermatopontin: a potential predictor for metastasis of human oral cancer. Int J Cancer 130: 2903-2911, 2012.
30. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW and Barrett JC: Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 59: 5724-5731, 1999.
31. Verburg FA, Wäschle K, Reiners C, Giovanella L and Lentjes EG: Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. Horm Metab Res 42: 736-739, 2010.
32. Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431, 2002. (Pubitemid 35414532)
33. Van der Auwera I, Van Laere SJ, Van den Bosch SM, et al: Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer 99: 1735-1742, 2008.
34. Kimura H, Hayashi-Takanaka Y, Goto Y, Takizawa N and Nozaki N: The organization of histone H3 modifications as revealed by a of specific monoclonal antibodies. Cell Struct Funct 33: 61-73, 2008. (Pubitemid 351860902)
35. Wang LL, Qiu GR, Fu WN, Yuan ZW and Sun KL: Transcriptional regulation of Fhl1 by estradiol in rat myoblastocytes. Steroids 75: 368-372, 2010.
36. Shen Y, Jia Z, Nagele RG, Ichikawa H and Goldberg GS: SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res 66: 1543-1552, 2006. (Pubitemid 43259936)
37. Fryknas M, Wickenberg-Bolin U, Goransson H, et al: Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol 27: 211-220, 2006.
38. Li X, Jia Z, Shen Y, et al: Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci 99: 1326-1333, 2008. (Pubitemid 351761720)
39. Yuan J, Luo RZ, Fujii S, et al: Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 63: 4174-4180, 2003. (Pubitemid 36917943)
40. Chen K, Sawhney R, Khan M, et al: Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 133: 1131-1138, 2007. (Pubitemid 350157026)
41. Henken FE, Wilting SM, Overmeer RM, et al: Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 97: 1457-1464, 2007. (Pubitemid 350114795)
42. Magdinier F and Wolffe AP: Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA 98: 4990-4995, 2001. (Pubitemid 32397070)
43. Cheung P and Lau P: Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 19: 563-573, 2005. (Pubitemid 40349431)
44. Hong S, Derfoul A, Pereira-Mouries L and Hall DJ: A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes. FASEB J 23: 3539-3552, 2009.